EcoDrugPlus

Imp (Inosine 5'-Monophosphate) Dehydrogenase 2

Ensembl ID : ENSOMYG00000047724
Gene Symbol: IMPDH2
2 Cross references
194 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSOMYG00000000773
Gene Symbol: JAK1
1 Cross references
205 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSOMYG00000008777
Gene Symbol: JAK1
1 Cross references
204 Possible Orthologues:

Janus Kinase 2

Ensembl ID : ENSOMYG00000014300
Gene Symbol: JAK2
1 Cross references
193 Possible Orthologues:

Janus Kinase 2a

Ensembl ID : ENSOMYG00000031302
Gene Symbol: JAK2A
1 Cross references
192 Possible Orthologues:

Janus Kinase 2b

Ensembl ID : ENSOMYG00000006066
Gene Symbol: JAK2B
1 Cross references
194 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSOMYG00000045906
Gene Symbol: LYN
1 Cross references
189 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSOMYG00000009192
Gene Symbol: LYN
1 Cross references
189 Possible Orthologues:

Malt Paracaspase 1

Ensembl ID : ENSOMYG00000003023
Gene Symbol: MALT1
1 Cross references
195 Possible Orthologues:

Mapk /erk Kinase

Ensembl ID : ENSOMYG00000024021
Gene Symbol: TMEK
2 Cross references
207 Possible Orthologues:

Mapk Activated Protein Kinase 2b

Ensembl ID : ENSOMYG00000032252
Gene Symbol: MAPKAPK2B
1 Cross references
168 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2a

Ensembl ID : ENSOMYG00000008832
Gene Symbol: MKNK2A
1 Cross references
155 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).